Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ERNA
stocks logo

ERNA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Ernexa Therapeutics Inc (ERNA.O) is -0.01, compared to its 5-year average forward P/E of -3.23. For a more detailed relative valuation and DCF analysis to assess Ernexa Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.23
Current PE
-0.01
Overvalued PE
3.52
Undervalued PE
-9.98

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 463.67% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 463.67% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ERNA News & Events

Events Timeline

(ET)
2025-12-02
09:00:00
Ernexa Appoints Dr. Ira Winer to Advisory Board
select
2025-11-10 (ET)
2025-11-10
08:37:56
Ernexa Therapeutics Announces Q3 Operating Loss of $2M Compared to $2.3M Last Year
select
2025-10-29 (ET)
2025-10-29
08:34:21
Ernexa Therapeutics and Cellipont Bioservices Form Partnership
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
11-11Newsfilter
Ernexa Therapeutics to Showcase at Oxford Global's Cell 2025 Event

  • Ernexa Therapeutics Presentation: Ernexa Therapeutics will present at Cell 2025 in London, focusing on the development of cell therapies for advanced cancer and autoimmune diseases, with CEO Sanjeev Luther leading discussions on clinical trial design and regulatory strategies.

  • Panel Discussion Insights: Luther will participate in a panel discussing the challenges of navigating development and the importance of funding, innovation, and regulatory engagement in advancing their engineered induced mesenchymal stem cell (iMSC) platform.

  • Event Overview: Cell 2025 is a key event for professionals in bioprocessing and advanced therapies, featuring discussions on the impact of AI and machine learning in the industry, and bringing together leaders from various sectors including pharma, biotech, and academia.

  • Ernexa's Core Technology: Ernexa Therapeutics specializes in engineering induced pluripotent stem cells (iPSCs) into allogeneic synthetic iMSCs, aiming to provide scalable, off-the-shelf treatments for conditions like ovarian cancer and autoimmune diseases.

[object Object]
Preview
7.5
11-06Newsfilter
Ernexa Therapeutics Highlights Collaboration with Cellipont Bioservices to Progress Towards First-in-Human Trials on Virtual Investor "What This Means" Platform

  • Company Announcement: Ernexa Therapeutics announced its participation in a Virtual Investor segment where CEO Sanjeev Luther discussed a partnership with Cellipont Bioservices to advance their lead cell therapy, ERNA-101, for ovarian cancer.

  • Partnership Focus: The partnership aims to enhance Engineering, Differentiation, and Production (EDP) activities to facilitate clinical manufacturing and trials for ERNA-101.

  • Innovative Technology: Ernexa is developing cell therapies using induced pluripotent stem cells (iPSCs) to create allogeneic synthetic mesenchymal stem cells (iMSCs), providing scalable treatment solutions without the need for patient-specific cell harvesting.

  • Product Overview: ERNA-101 is designed to activate the immune system against cancer cells, while ERNA-201 targets inflammation for autoimmune diseases, with the initial focus on ovarian cancer treatment.

[object Object]
Preview
2.0
10-30TipRanks
Three Penny Stocks to Keep an Eye on as of October 30, 2025

  • Penny Stocks to Watch: Cambium Networks, Purple Biotech, and Ernexa Therapeutics are highlighted as top penny stocks to monitor on October 30, 2025, based on their significant Dollar Volume and stock price movements.

  • Cambium Networks: The company experienced a Dollar Volume of $1.54 billion and a stock price increase of 377% following its integration with SpaceX's Starlink, enhancing its telecommunications solutions.

  • Purple Biotech: This clinical-stage biopharmaceutical company saw a Dollar Volume of $438.91 million and an 81% stock price surge after announcing a production milestone for its cancer treatment antibody, IM1240.

  • Ernexa Therapeutics: With a Dollar Volume of $375.25 million and a nearly 41% stock price rise, Ernexa is advancing its lead cell therapy for ovarian cancer through a partnership with Cellipont Bioservices.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ernexa Therapeutics Inc (ERNA) stock price today?

The current price of ERNA is 1.31 USD — it has increased 13.91 % in the last trading day.

arrow icon

What is Ernexa Therapeutics Inc (ERNA)'s business?

Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.

arrow icon

What is the price predicton of ERNA Stock?

Wall Street analysts forecast ERNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ERNA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ernexa Therapeutics Inc (ERNA)'s revenue for the last quarter?

Ernexa Therapeutics Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What is Ernexa Therapeutics Inc (ERNA)'s earnings per share (EPS) for the last quarter?

Ernexa Therapeutics Inc. EPS for the last quarter amounts to -0.15 USD, decreased -99.80 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ernexa Therapeutics Inc (ERNA)'s fundamentals?

The market is revising No Change the revenue expectations for ERNA for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 4.38%.
arrow icon

How many employees does Ernexa Therapeutics Inc (ERNA). have?

Ernexa Therapeutics Inc (ERNA) has 6 emplpoyees as of December 05 2025.

arrow icon

What is Ernexa Therapeutics Inc (ERNA) market cap?

Today ERNA has the market capitalization of 10.20M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free